Adagene (ADAG) Competitors $1.45 -0.09 (-5.84%) Closing price 04/8/2025 03:58 PM EasternExtended Trading$1.45 0.00 (-0.28%) As of 04/8/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ADAG vs. TECX, ORKA, MREO, BNTC, AURA, CYRX, RNAC, TSVT, AQST, and TSHAShould you be buying Adagene stock or one of its competitors? The main competitors of Adagene include Tectonic Therapeutic (TECX), Oruka Therapeutics (ORKA), Mereo BioPharma Group (MREO), Benitec Biopharma (BNTC), Aura Biosciences (AURA), Cryoport (CYRX), Cartesian Therapeutics (RNAC), 2seventy bio (TSVT), Aquestive Therapeutics (AQST), and Taysha Gene Therapies (TSHA). These companies are all part of the "pharmaceutical products" industry. Adagene vs. Tectonic Therapeutic Oruka Therapeutics Mereo BioPharma Group Benitec Biopharma Aura Biosciences Cryoport Cartesian Therapeutics 2seventy bio Aquestive Therapeutics Taysha Gene Therapies Tectonic Therapeutic (NASDAQ:TECX) and Adagene (NASDAQ:ADAG) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, community ranking, institutional ownership, profitability, media sentiment, valuation, risk, dividends and analyst recommendations. Is TECX or ADAG more profitable? Adagene's return on equity of 0.00% beat Tectonic Therapeutic's return on equity.Company Net Margins Return on Equity Return on Assets Tectonic TherapeuticN/A -35.53% -31.97% Adagene N/A N/A N/A Do insiders & institutionals have more ownership in TECX or ADAG? 62.6% of Tectonic Therapeutic shares are held by institutional investors. Comparatively, 9.5% of Adagene shares are held by institutional investors. 9.2% of Tectonic Therapeutic shares are held by insiders. Comparatively, 21.2% of Adagene shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has better earnings & valuation, TECX or ADAG? Tectonic Therapeutic has higher earnings, but lower revenue than Adagene. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTectonic TherapeuticN/AN/A$12.16M-$6.53-2.25Adagene$103.20K661.89-$18.95MN/AN/A Does the media refer more to TECX or ADAG? In the previous week, Adagene had 8 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 8 mentions for Adagene and 0 mentions for Tectonic Therapeutic. Tectonic Therapeutic's average media sentiment score of 1.31 beat Adagene's score of 0.73 indicating that Tectonic Therapeutic is being referred to more favorably in the media. Company Overall Sentiment Tectonic Therapeutic Positive Adagene Positive Does the MarketBeat Community prefer TECX or ADAG? Adagene received 14 more outperform votes than Tectonic Therapeutic when rated by MarketBeat users. However, 100.00% of users gave Tectonic Therapeutic an outperform vote while only 79.31% of users gave Adagene an outperform vote. CompanyUnderperformOutperformTectonic TherapeuticOutperform Votes9100.00% Underperform VotesNo VotesAdageneOutperform Votes2379.31% Underperform Votes620.69% Do analysts recommend TECX or ADAG? Tectonic Therapeutic currently has a consensus target price of $77.75, indicating a potential upside of 429.99%. Adagene has a consensus target price of $8.00, indicating a potential upside of 451.72%. Given Adagene's higher probable upside, analysts clearly believe Adagene is more favorable than Tectonic Therapeutic.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tectonic Therapeutic 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17Adagene 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has more volatility & risk, TECX or ADAG? Tectonic Therapeutic has a beta of 2.87, suggesting that its share price is 187% more volatile than the S&P 500. Comparatively, Adagene has a beta of 0.61, suggesting that its share price is 39% less volatile than the S&P 500. SummaryTectonic Therapeutic beats Adagene on 8 of the 15 factors compared between the two stocks. Remove Ads Get Adagene News Delivered to You Automatically Sign up to receive the latest news and ratings for ADAG and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADAG vs. The Competition Export to ExcelMetricAdagenePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$68.31M$6.10B$5.08B$6.91BDividend YieldN/A2.91%5.34%4.23%P/E RatioN/A6.5321.2317.05Price / Sales661.89185.43349.8385.96Price / CashN/A65.6738.1534.64Price / Book0.905.356.023.66Net Income-$18.95M$141.19M$3.19B$247.27M7 Day Performance-11.59%-12.28%-8.88%-9.80%1 Month Performance-28.57%-20.11%-6.84%-12.84%1 Year Performance-51.51%-22.71%0.58%-10.68% Adagene Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADAGAdagene2.3223 of 5 stars$1.45-5.8%$8.00+451.7%-48.8%$68.31M$103,204.000.00260Analyst RevisionTECXTectonic Therapeutic3.0906 of 5 stars$15.53-0.6%$77.75+400.6%N/A$289.84MN/A-2.64120Positive NewsGap UpORKAOruka Therapeutics2.8664 of 5 stars$7.62-2.7%$39.86+423.1%N/A$285.30MN/A-1.22N/ANews CoveragePositive NewsGap UpHigh Trading VolumeMREOMereo BioPharma Group2.4248 of 5 stars$1.83-8.0%$7.71+321.5%-44.5%$283.92M$1M-30.5040Gap UpHigh Trading VolumeBNTCBenitec Biopharma2.0621 of 5 stars$12.02-2.4%$24.43+103.2%+99.3%$281.88M$80,000.00-7.9620AURAAura Biosciences1.9411 of 5 stars$5.52+1.7%$22.75+312.1%-28.0%$277.24MN/A-3.1950Gap DownCYRXCryoport2.6211 of 5 stars$5.49+2.8%$11.83+115.5%-73.4%$274.01M$228.39M-1.621,020Gap UpRNACCartesian Therapeutics1.7837 of 5 stars$10.11+1.1%$42.14+316.8%-27.4%$261.92M$38.91M-0.1964News CoverageGap DownTSVT2seventy bio2.1028 of 5 stars$4.95flat$6.67+34.7%-11.3%$259.07M$37.86M-2.66440Analyst ForecastHigh Trading VolumeAQSTAquestive Therapeutics1.3461 of 5 stars$2.62-3.3%$10.57+303.5%-41.8%$259.04M$57.56M-5.82160Analyst RevisionPositive NewsGap DownTSHATaysha Gene Therapies2.0844 of 5 stars$1.24+1.6%$6.63+434.3%-57.8%$254.20M$8.33M1.97180Gap Up Remove Ads Related Companies and Tools Related Companies TECX Competitors ORKA Competitors MREO Competitors BNTC Competitors AURA Competitors CYRX Competitors RNAC Competitors TSVT Competitors AQST Competitors TSHA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ADAG) was last updated on 4/9/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredElon’s Silver Play? Trump Clears the PathNothing is confirmed—yet. But Musk has disrupted every industry he's touched, and Trump's policies make the ti...Priority Gold | SponsoredAll Signs Point To Collapse - 401(k)s/IRAs /Are DoomedRetiring? Not so Fast..Hold Onto Your Bootstraps For A Long Road AheadAmerican Hartford Gold | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adagene Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adagene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
